• Products Verify Guide
  • Language
    • ”English”
    • ”Español”
    • ”Français”
    • ”русский”
    • ”中文”
    • ”العربية”
    • ”português”
  • News & Media
  • FAQ
  • Contact Us
Tagrix
  • Home
  • The Tagrix
    • Taking Tagrix
    • How Tagrix Works
    • Side Effects
    • Prescribing Info
  • The Manufacturer
    • Beacon at a Glance
    • Facilities
    • Quality Policy
    • CSR
  • Lung Cancer
    • Possible Treatments
  • Order Now
Select Page

The-Manufacturer

Sep 13, 2016 | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent Posts

  • Third-generation inhibitors targeting EGFR T790M mutation in advanced NSCLC
  • Osimertinib Given as First-Line Treatment May Alter Biology of EGFR-Mutated NSCLC
  • Osimertinib approved in EU as first-in-class treatment for NSCLC
  • Osimertinib Given as First-line Treatment May Alter Biology of EGFR-Mutated Non-Small-Cell Lung Cancer

GLOBAL MARKETING PARTNER

Beacon Medicare Limited 9/B/2,Toyenbee Circular Road, Motijheel,Dhaka-1223, Bangladesh Phone: +880-2-57165371/79 Fax: +880 2-8870109 Web: beaconmedicare.com.bd

HEAD OFFICE

Beacon Pharmaceuticals Limited
9/B/2,Toyenbee Circular Road,
Motijheel,Dhaka-1223, Bangladesh
Phone: +880-2-57165371/79
Fax: +880-2-57165379
Email: info@beaconmedicare.com.bd
Web: beaconpharma.com.bd

SR. VICE PRESIDENT

Skype ID: shahariar_tamal
WhatsApp: +8801922121404
WeChat: +8801922121404
IMO: +8801922121404
Viber: +8801922121404
Email: tamal@beaconmedicare.com.bd
beaconbdd@gmail.com
  • Facebook
  • Twitter

Copyright © 2021 tagrix.net | All Rights Reserved | Developed by Beacon Medicare Limited